SIRPA and cancer: Therapeutic CD47 antibodies and decoys designed to inhibit the function of CD47 have entered multiple clinical trials for treating cancers, but anemia associated with loss of CD47-dependent inhibitory SIRPα signaling in macrophages has been a frequent side effect observed for the first generation of these therapeutics (Kaur et al., 2020).